Jeffrey S. Berger, MD, MS, FAHA, FACC
Print Faculty Schedule:
|
SCHEDULE FOR VEITHsymposium™ |
Wednesday, November 20, 2019 |
Presenter
Highlights Of The New AHA Guidelines For Management Of Cholesterol Levels: What LDL-C Levels Should We Strive For In Our Vascular Patients: Why Are Non-HDL Levels A Better Indicator Of Atherosclerotic Risk Than LDL-C Levels
7:16 AM - 7:21 AM
|
Presenter
Current Value Of Antithrombotic And Antiplatelet Therapy In Vascular Patients: What Drugs Should They Be On – When And Why: The COMPASS RCT Shows That Low Dose Rivaroxaban And Aspirin Decreases Death, Stroke And MI In Vascular Patients: What About Aspirin Alone
7:28 AM - 7:33 AM
|
Presenter
New RCT Evidence Shows That An Omega 3 Fatty Acid Formula, Vascepa, Reduces By 25% Major Adverse Cardiac Events In Patients With High Triglycerides (The REDUCE-IT Trial): Bempedoic Acid Reduces LDL-C And C-Reactive Protein: Improved Best Medical Treatment Will Sharply Decrease The Need For Interventional Treatments
7:47 AM - 7:52 AM
|
previous | next |